These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25392236)

  • 1. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.
    Dillingham BC; Knoblach SM; Many GM; Harmon BT; Mullen AM; Heier CR; Bello L; McCall JM; Hoffman EP; Connor EM; Nagaraju K; Reeves EKM; Damsker JM
    Cell Mol Neurobiol; 2015 Apr; 35(3):377-387. PubMed ID: 25392236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.
    Damsker JM; Conklin LS; Sadri S; Dillingham BC; Panchapakesan K; Heier CR; McCall JM; Sandler AD
    Inflamm Res; 2016 Sep; 65(9):737-43. PubMed ID: 27261270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases of M2a macrophages and fibrosis in aging muscle are influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide.
    Wang Y; Wehling-Henricks M; Samengo G; Tidball JG
    Aging Cell; 2015 Aug; 14(4):678-88. PubMed ID: 26009878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
    Grounds MD; Lloyd EM
    J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
    Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
    Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
    Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset.
    Damsker JM; Cornish MR; Kanneboyina P; Kanneboyina I; Yu Q; Lipson R; Phadke A; Knoblach SM; Panchapakesan K; Morales M; Fiorillo AA; Partridge T; Nagaraju K
    Inflamm Res; 2019 Nov; 68(11):969-980. PubMed ID: 31446438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
    Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
    Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
    Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
    Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
    Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
    Akkad H; Cacciani N; Llano-Diez M; Corpeno Kalamgi R; Tchkonia T; Kirkland JL; Larsson L
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13172. PubMed ID: 30120816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy.
    Batra A; Harrington A; Lott DJ; Willcocks R; Senesac CR; McGehee W; Xu D; Mathur S; Daniels MJ; Rooney WD; Forbes SC; Triplett W; Deol JK; Arpan I; Bendixen R; Finkel R; Finanger E; Tennekoon G; Byrne B; Russman B; Sweeney HL; Walter G; Vandenborne K
    Am J Phys Med Rehabil; 2018 Oct; 97(10):734-740. PubMed ID: 29734234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Pien Tze Huang on Experimental Autoimmune Encephalomyelitis Rat.
    Qiu X; Luo H; Liu X; Guo Q; Zheng K; Fan D; Shen J; Lu C; He X; Zhang G; Lu A
    J Immunol Res; 2018; 2018():2952471. PubMed ID: 29682587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.
    Hoffman EP; Riddle V; Siegler MA; Dickerson D; Backonja M; Kramer WG; Nagaraju K; Gordish-Dressman H; Damsker JM; McCall JM
    Steroids; 2018 Jun; 134():43-52. PubMed ID: 29524454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor.
    Wells E; Kambhampati M; Damsker JM; Gordish-Dressman H; Yadavilli S; Becher OJ; Gittens J; Stampar M; Packer RJ; Nazarian J
    Oncotarget; 2017 Feb; 8(6):9366-9374. PubMed ID: 28030841
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.